MARKET

JANX

JANX

Janux Therapeutics, Inc.
NASDAQ
16.67
+0.37
+2.27%
Opening 14:17 09/28 EDT
OPEN
16.57
PREV CLOSE
16.30
HIGH
16.77
LOW
16.16
VOLUME
211.75K
TURNOVER
--
52 WEEK HIGH
35.34
52 WEEK LOW
12.12
MARKET CAP
1.02B
P/E (TTM)
-10.1411
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at JANX last week (0921-0925)?
Weekly Report · 8h ago
Weekly Report: what happened at JANX last week (0914-0918)?
Weekly Report · 09/21 09:56
Janux Therapeutics: It's Too Early To Tell If Prostate Cancer Program Can Succeed
Seeking Alpha · 09/18 16:46
Janux’s New Prostate Cancer Combo Trial: What Early Signals Could Mean for JANX
TipRanks · 09/17 16:30
The Zacks Analyst Blog Highlights Pfizer, Novartis, Candel and Janux
NASDAQ · 09/16 09:47
Janux Therapeutics Doses First Patient In The Phase 1 Clinical Trial For JANX013, Its PSMA-Targeted Tumor-Activated CD28 Co-Stimulatory Bispecific, In Patients With Metastatic Castration-Resistant Prostate Cancer
Benzinga · 09/14 12:07
Weekly Report: what happened at JANX last week (0907-0911)?
Weekly Report · 09/14 10:00
Weekly Report: what happened at JANX last week (0831-0904)?
Weekly Report · 09/07 09:55
More
About JANX
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed three bispecific platforms: Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM). Its TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain. Its TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidates include JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr) designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors. JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and others.

Webull offers Janux Therapeutics Inc stock information, including NASDAQ: JANX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JANX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading JANX stock methods without spending real money on the virtual paper trading platform.